P Llopis-Salvia1, N V Jiménez-Torres. 1. Pharmacy Department, Hospital de la Ribera, Alzira, Valencia, Spain. pllopis@hosptial-ribera.com
Abstract
BACKGROUND: Intensive care unit patients are a highly heterogeneous population. Accurate dosing for this population requires characterization of the appropriate pharmacokinetic parameters. OBJECTIVE: To estimate population pharmacokinetic parameters of vancomycin (VAN) in adult critically ill patients and to establish the predictive performance of the resulting model. PATIENTS AND METHOD: Fifty critically ill patients with suspected or documented infection with VAN-sensitive micro-organisms were included. Thirty patients and 234 serum concentration-time sets obtained during clinical routine monitoring were used to estimate the pharmacokinetic parameters (group A). An open bicompartimental model with intermittent intravenous administration was used to adjust the data. Data were evaluated using a nonlinear mixed effects model (nonmem software). Forty plasma concentration-time data sets from 20 patients were used for validation using the Bayesian method (group B). RESULTS: There was a linear relationship between creatinine clearance (Cl(cr)) and VAN clearance (Cl(VAN)). The inclusion of the non-renal clearance (Cl(nr)) (intercept of Cl(VAN) vs. Cl(cr) relationship) improved the model significantly (Cl(nr) 17 mL/min). The volume of distribution seems to be larger than previously reported: volume of the central compartment (V(c)) was 0.41 L/kg and volume of the peripheral compartment was (V(p)), 1.32 L/kg. The mean error (bias) and mean absolute error (precision) for predicting subsequent peak concentrations were -2.16 and 9.28 mg/L and for trough concentrations, -0.22 and 3.87 mg/L respectively. CONCLUSION: The use of population-specific pharmacokinetic parameters and Bayesian forecasting improves dosage-regimen design.
BACKGROUND: Intensive care unit patients are a highly heterogeneous population. Accurate dosing for this population requires characterization of the appropriate pharmacokinetic parameters. OBJECTIVE: To estimate population pharmacokinetic parameters of vancomycin (VAN) in adult critically ill patients and to establish the predictive performance of the resulting model. PATIENTS AND METHOD: Fifty critically ill patients with suspected or documented infection with VAN-sensitive micro-organisms were included. Thirty patients and 234 serum concentration-time sets obtained during clinical routine monitoring were used to estimate the pharmacokinetic parameters (group A). An open bicompartimental model with intermittent intravenous administration was used to adjust the data. Data were evaluated using a nonlinear mixed effects model (nonmem software). Forty plasma concentration-time data sets from 20 patients were used for validation using the Bayesian method (group B). RESULTS: There was a linear relationship between creatinine clearance (Cl(cr)) and VAN clearance (Cl(VAN)). The inclusion of the non-renal clearance (Cl(nr)) (intercept of Cl(VAN) vs. Cl(cr) relationship) improved the model significantly (Cl(nr) 17 mL/min). The volume of distribution seems to be larger than previously reported: volume of the central compartment (V(c)) was 0.41 L/kg and volume of the peripheral compartment was (V(p)), 1.32 L/kg. The mean error (bias) and mean absolute error (precision) for predicting subsequent peak concentrations were -2.16 and 9.28 mg/L and for trough concentrations, -0.22 and 3.87 mg/L respectively. CONCLUSION: The use of population-specific pharmacokinetic parameters and Bayesian forecasting improves dosage-regimen design.
Authors: Jennifer Le; Edmund V Capparelli; Uzra Wahid; Yi Shuan S Wu; Gale L Romanowski; Tri M Tran; Austin Nguyen; John S Bradley Journal: Clin Ther Date: 2015-05-29 Impact factor: 3.393
Authors: Lyndsay M van de Vijsel; Sandra A N Walker; Scott E Walker; Sharon Yamashita; Andrew Simor; Michelle Hladunewich Journal: Can J Hosp Pharm Date: 2010-05
Authors: N Maki; A Ohkuchi; Y Tashiro; M R Kim; M Le; T Sakamoto; S Matsubara; Y Hakamata Journal: Eur J Clin Microbiol Infect Dis Date: 2012-03-06 Impact factor: 3.267
Authors: Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall Journal: Expert Rev Anti Infect Ther Date: 2010-01 Impact factor: 5.091
Authors: Tingjie Guo; Reinier M van Hest; Luca F Roggeveen; Lucas M Fleuren; Patrick J Thoral; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Paul W G Elbers Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191